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Short title: Family history of cancer and childhood hematopoietic malignancies 
Type of article: Research article in epidemiology 
Key words: family history, cancer, children, acute leukemia, Hodgkin’s lymphoma, non-
Hodgkin’s lymphoma 
Abbreviations used:  AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute 
myeloblastic leukemia; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; CI, 
confidence interval; OR, odds ratio; ENT, ear, nose or throat. 
Novelty and impact of our paper: This paper investigated in detail family history of cancer in 
children with leukemia and lymphoma in France at a national scale. We report that cancers 
were more frequent in the first and second-degree relatives of lymphoma cases than in 
population controls, and the associations were stronger for a family history of Hodgkin's 
lymphoma. 
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Abstract 
The role of a family history of cancer in the etiology of childhood hematopoietic malignancies 
was investigated using the data from the ESCALE study. ESCALE, a population-based case-
control study, was carried out in France over the period, 2003-2004. A total of 773 cases of 
acute leukemia (AL), 130 of Hodgkin’s lymphoma (HL), 163 of non-Hodgkin’s lymphoma 
(NHL) and 1681 population-based controls were included. The controls were randomly 
selected from the French population and were frequency matched with the cases on age and 
gender. Cancer history in first- and second-degree relatives was reported by the mothers in a 
structured telephone questionnaire which was the same for the cases and controls. Odds 
ratios (ORs) were estimated using an unconditional regression model taking into account the 
stratification variables and potential confounders. A family history of cancer was associated 
with an increased risk of HL (OR = 1.5 [1.0-2.2]) and NHL (OR = 1.8 [1.3-2.5]), but not AL 
(OR = 1.0 [0.9-1.2]). The ORs were higher when at least two relatives had a history of cancer 
or when one case occurred before age 46 years. Only HL was significantly associated with a 
family history of hematopoietic malignancies (OR = 2.0 [1.0-3.8]), mainly because of a 
significant association with a history of Hodgkin's lymphoma (OR = 5.4 [1.3-22]). In 
conclusion, the study findings support the hypothesis of familial susceptibility to childhood 
lymphoma, but do not suggest familial susceptibility to childhood acute leukemia. 
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Introduction 
Specific genetic syndromes play a role in the etiology of only a very small proportion of 
hematopoietic malignancies in children 1, 2. The syndromes include familial neoplastic 
syndromes, inherited immunodeficiency and bone marrow failure syndromes 1. The potential 
role of inherited susceptibility in childhood acute leukemia and lymphoma has yet to be 
elucidated. Large population-based registry-linked studies have investigated the familial 
aggregation of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma or leukemia 3-7. In children, 
few population-based registry-linked studies have been published 8-13, most of them relating 
to first-degree relatives 8-12. The estimated relative risks for a positive family history of cancer 
ranged from 0.8 to 1.0 for childhood leukemia 8, 10-13 and from 1.0 to 1.8 for childhood 
lymphoma taken as a whole 8, 10-12. A number of case-control studies have addressed the 
association between history of cancer in first and second degree relatives of children with 
leukemia  and observed OR from 1.1 to 1.6 14-18. Only one case-control study has been 
published for childhood Hodgkin’s lymphoma and non-Hodgkin’s lymphoma 15. Overall the 
number of published studies in children is weak, particularly for lymphomas. The aim of the 
present study was to investigate the association between childhood acute leukemia (AL), 
Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) and a family history of cancer 
in the first- and second-degree relatives of the index children. 
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Patient and methods 
The ESCALE study was a French national population-based case-control study conducted in 
2003 and 2004 to investigate the role of infectious, environmental and genetic factors in four 
childhood neoplastic diseases. The present paper focuses on acute leukemia (AL), 
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). 
 
Case and control ascertainment 
The cases were identified directly by the investigators assigned to each French pediatric 
oncology hospital department, with the support of the French National Registry of Childhood 
Blood Malignancies 19. In order for the cases to be eligible, leukemia or lymphoma was to 
have been newly diagnosed between January 1, 2003, and December 31, 2004. The cases 
were also required to be aged less than 15 years and resident in France at the time of 
diagnosis. Cases who had been adopted, or whose biological mother had died, or whose 
mother did not speak French or whose mother presented with a psychiatric disorder were not 
eligible. For ethical reasons, the mothers of children who had died or who were receiving 
hospital palliative care were not eligible. Out of the 1321 cases (945 AL, 169 HL, 207 NHL) of 
childhood hematopoietic malignancies identified during the study period, 1188 (851 AL, 151 
HL, 186 NHL) cases were eligible. The reasons for non-eligibility consisted in the child’s 
death (34 AL, 3 HL, 7 NHL), hospital palliative care (7 AL), biological mother’s death (10 AL, 
3 NHL), non-French-speaking mother (29 AL, 11 HL, 8 NHL) or mother with serious 
psychiatric disorders (14 AL, 4 HL, 3 NHL). 
The participation rates were 91, 86 and 88% for acute leukemia, Hodgkin's lymphoma and 
non-Hodgkin's lymphoma, respectively. 
 
The controls were randomly selected from the French population using a quota sampling 
method. A first sample of 60,000 addresses representative of the French population in terms 
of region and degree of urbanization was constituted from the French national telephone 
directory (plus randomly generated unlisted numbers). The quotas were designed to make 
the controls similar to all the cases of all types of cancer in term of age and gender, using the 
French National Registry of Childhood Blood Malignancies 19 and the Regional Childhood 
cancer Registries 20 as reference. Additional quotas were used to ensure that the control 
group was also representative of the French general population in terms of the number of 
children aged under 15 years living in the household, conditionally on age, based on the 
1999 population census. Like the cases, the controls were not to have been adopted and 
were to have a biological mother who could be interviewed (alive, not presenting with a 
serious psychiatric disorder and French- speaking). 
Out of the 50,217 phone numbers dialed, 22,584 did not connect to a home number, 24,410 
were ineligible, and, for 862, the respondent hung up before eligibility could be checked. For 
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the 2,361 remaining numbers, there were 679 refusals to participate. Thus, 1,682 mothers 
were interviewed (71.2%). One control with a history of neuroblastoma was excluded and 
1681 children were included as controls. 
 
Data collection 
The telephone interviews with the cases’ and controls’ biological mothers were carried out by 
the same trained interviewers using structured questionnaires. The cases’ mothers were 
interviewed at least 2 months after the diagnosis. The telephone questionnaire elicited 
information on demographic and socioeconomic characteristics, country of birth of each 
grand-parent, parental occupational history, childhood environment, and personal and 
familial medical history. The first- (parents and siblings) and second-degree (grandparents, 
uncles, aunts, half-brothers and half-sisters, but not the nephews and nieces of index 
children) genealogy was elicited and, for each relative, the mother was asked whether he or 
she had ever had a diagnosis of leukemia, Hodgkin’s disease, lymphoma, myeloma or a 
solid tumor in any of the following disease sites: oral cavity or ENT (ear, nose or throat); lung; 
esophagus or  stomach; liver; colon, rectum or anus; breast; thyroid; skin; melanoma; bone; 
kidney; bladder; uterus or ovary; prostate; or brain. An open question targeted other or 
unclearly-specified disease sites. The date of, or age at, diagnosis was also elicited. 
 
Statistical analysis 
Separate analyses by childhood hematopoietic malignancy and leukemia subtype (i.e., acute 
lymphoblastic leukemia [ALL] and acute myeloblastic leukemia [AML]) were carried out. 
Unconditional logistic regression was used to estimate the odds ratios (OR) and 95% 
confidence intervals (CI), with adjustment for the stratification variables, age and gender. The 
analyses were restricted to children aged 5 years or more for Hodgkin's lymphomas and 2 
years or more for non-Hodgkin's lymphomas because of the small numbers of cases in the 
lowest age groups. Family history was analyzed for all family members and separately for 
first- and second-degree relatives. The malignancies in relatives were considered by disease 
site, by group of disease sites and as a whole. Further analyses investigated the role of the 
relative’s relationship to the case-control status (paternal or maternal relative), the age at 
onset of the earliest cancer in the family, and the total number of relatives with a cancer in 
the family. Investigation for and taking account of potential confounding by the age and 
number of relatives were conducted. The relative’s age was his/her age at the time of 
interview or death. The analyses were repeated after excluding the children with Down's 
syndrome. A sensitivity analysis was also conducted to evaluate the extent of a potential 
survival bias by allocating a positive family history of cancer to cases excluded because of 
death or hospital palliative care. Additional analyses by hematopoietic malignancy (AL, HL, 
NHL) and leukemia subtype (ALL, AML) were carried out using the polytomous logistic 
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regression model. Additional analyses were also carried out by HL and NHL subtypes. The 
SAS® software package (version 9, Cary, North Carolina) was used for all the analyses. All p 
values were two-tailed. 
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Results 
The cases consisted in 1066 children with an incident hematopoietic malignancy: 773 cases 
of acute leukemia (654 ALL, 101 AML, and 18 unspecified or biphenotypic AL), 130 of 
Hodgkin's lymphoma, of whom 128 aged more than 4 years (19 mixed cell, 79 nodular 
sclerosis, 17 lymphocyte predominant, 1 lymphocyte depleted and 12 not other specified 
HL), and 163 of non-Hodgkin's lymphoma, of whom 162 aged more than 1 year (73 Burkitt, 
20 anaplastic large cell, 37 B-cell lymphoblastic and 27 T-cell lymphoblastic, and 5 
unspecified NHL). 
 
Case and control comparability 
The distribution of the cases and controls by the quota variable combining age and gender is 
shown in table 1. The cases and controls were similar with respect to that variable for the 
study as a whole, but not for each hematopoietic malignancy. In particular, the lymphoma 
cases were significantly older than the controls. All the strata contained more than one 
control per case for adjustment, with more controls per lymphoma case in the youngest 
strata. The controls’ parents were slightly more educated and had a higher professional 
status than the parents of the leukemia and Hodgkin's lymphoma cases (table 2). There was 
no significant difference between the cases and controls in terms of the mothers’ or grand-
parents’ ages and the number of family members, after controlling for child age and gender. 
Consanguinity within first and second degree relatives was observed in none of the cases or 
controls. 
  
Family history of cancer 
The ORs associated with a positive family history of cancer in first-degree relatives, second-
degree relatives and first- and second-degree relatives are shown in table 3. A family history 
of cancer was positively associated with childhood Hodgkin's lymphoma and non-Hodgkin's 
lymphoma (HL: OR = 1.5 [1.0-2.2]; NHL: OR = 1.8 [1.3-2.5]). No association with acute 
leukemia was observed (AL: OR = 1.0 [0.9-1.2]). A positive family history of cancer was 
reported for 42% of the acute leukemia, 61% of the Hodgkin's lymphoma and 61% of the 
non-Hodgkin's lymphoma cases and 42% of the controls. For each childhood hematopoietic 
malignancy, the ORs were higher when at least two relatives had had a cancer or when at 
least one family member had experienced a malignancy before age 46 years. The ORs 
associated with a history of malignancy in a paternal relative were higher than those for a 
history of malignancy in a maternal relative for acute leukemia, but not for either type of 
lymphoma. 
Table 4 shows the results by disease site and group of sites. A family history of 
hematopoietic malignancy was only associated with Hodgkin's lymphoma (AL: OR = 1.0 [0.6-
1.5]; HL: OR = 2.0 [1.0-3,8]; NHL: OR = 1.0 [0.5-2.1]). Hodgkin's lymphoma was statistically 
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significantly associated with a family history of lymphoma (OR = 3.2 [1.2-8.0]) and, more 
particularly, with a history of Hodgkin's lymphoma (OR = 5.4 [1.3-22]). There were significant 
associations between childhood acute leukemia and a family history of uterine or ovarian 
cancer (OR = 1.6 [1.1-2.4]). Family history of cancer of the colon, rectum or anus was 
statistically significantly associated with both childhood Hodgkin’s (OR = 2.4 [1.0-5.4]) and 
non-Hodgkin's (OR = 2.4 [1.2-4.7]) lymphomas. Non-Hodgkin's lymphoma was also 
statistically significantly associated with a family history of testicular (OR = 6.3 [1.4-29]), 
uterine/ovarian (OR = 2.6 [1.4-4.8]), and pancreas cancer (OR = 3.4 [1.0-11]). 
The analyses by lymphoma subtypes were based on small numbers. A family history of 
cancer was significantly associated with anaplastic large cell lymphoma (OR = 4.4 [1.4-13.3]) 
and T cell lymphoblastic lymphoma (OR = 3.0 [1.3-6.9]), while ORs of 1.5 (95%CI: [0.9-2.4]) 
and 1.4 (95%CI: [0.7-2.7]) were observed for Burkitt’s lymphoma and B-cell lymphoblastic 
lymphoma, respectively. With respect to Hodgkin’s lymphoma, ORs were of 2,1 (95%CI: [0.8-
5.5]), 1.2 (95%CI: [0.7-1,9]), 1.8 (95%CI: [0.7-5.0]) for mixed cellularity, nodular sclerosis and 
lymphocyte predominant subtypes, respectively. The lymphocyte predominant subtype was 
significantly related to family history of Hematopoietic malignancy (OR = 5.1 [1.6-16.5]). 
 
The results were unchanged after exclusion of the children with Down's syndrome. The use 
of polytomous logistic regression models for ALL and AML, for AL and NHL (restricted to age 
greater than or equal to 2 years), and for AL, HL and NHL (restricted to age greater than or 
equal to 5 years) did not alter the results. With regard to potential confounders, no variable 
was statistically significantly associated with both a childhood hematopoietic malignancy and 
a family history of cancer, after controlling for child age and gender. Neither parental 
professional category nor educational level was associated with a family history of cancer in 
the control group. The results were also unchanged when the analyses were adjusted for 
familial structure (mother’s and father’s ages, mean ages of grand-parents and of uncles and 
aunts, number of relatives), socioeconomic status (professional category, educational level, 
degree of urbanization of the place of residence), breast-feeding and early infections, which 
have been previously shown to be related to leukemia in the literature and were also related 
in this study 21. The results were unchanged after exclusion of the children who had at least 
one grandparent born in Africa or Asia. 
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Discussion 
A positive association with a family history of cancer was observed for non-Hodgkin's 
lymphoma and Hodgkin's lymphoma, but not for acute leukemia. Only Hodgkin's lymphoma 
was associated with a positive family history of hematopoietic malignancy, mainly due to the 
high OR for family history of Hodgkin's lymphoma. Significant positive associations were also 
observed with a family history of solid tumor in the following disease sites: colon/rectum/anus 
with Hodgkin’s and non-Hodgkin's lymphoma; uterine/ovarian with non-Hodgkin's lymphoma 
and acute leukemia; and testicular and pancreas with non-Hodgkin's lymphoma. The 
numbers were too small to allow the analysis of leukemia or lymphoma aggregation 
separately for the first and second degrees. 
 
Genetic susceptibility could be reflected by an increased familial incidence and earlier onset 
of malignancies. Indeed, for lymphoma, the ORs were higher when at least two relatives had 
presented with cancer or when the age at diagnosis of a single case was less than 46 years. 
This tendency was also observed, at a lesser extent, for leukemia; a weak genetic 
susceptibility to leukemia cannot be then excluded with regard to our results.  
 
With an alpha error of 5%, the statistical power of the study to evidence an OR of 1.5, which 
was the order of magnitude of the relationship between childhood AL and family history of 
cancer in three previous case-control studies 15-17, was greater than 99%. 
The relatives were quite young: the mean age of the parents at the time of the interview was 
about 40 years; that of the grand-parents about 65 years. A lack of statistical power for 
specific types of cancer with a high age of onset is therefore probable. The positive results 
for cancers with lower ages of onset were less censored. 
 
The cases were identified through the data collection system of the French National Registry 
of Childhood Blood Malignancies, making case selection at the identification stage unlikely. 
Cases who had died or were receiving palliative care (41 AL, 3 HL and 7 NHL) were not 
eligible. However, the absence of a relationship between leukemia and family history of 
cancer is unlikely to result from a survival bias. The severity of leukemia is not known to be 
related to family history, and, in the present study, the leukemia cases who died during the 
year following the telephone interview had an even less frequently positive family history of 
cancer than the survivors (35% vs 42%). All of the 41 ineligible leukemia cases who had died 
or were receiving palliative care would have had to have a positive family history of cancer in 
order for cases selection to have masked a slight association, with a corresponding OR of 
1.2 (95%CI: [1.0-1.4]), instead of the observed one of 1.0 (95%CI: [0.9-1.2]). None of the 
lymphoma cases eligible during the study period had a known ataxia telangiectasia or any 
other genetic syndrome reported in the French National Registry of Childhood Blood 
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Malignancies. Therefore, a selection by survival of cases related to these familial rare 
diseases is unlikely. 
 
The controls were randomly selected from the overall population. The national telephone 
directory was used as the basis for random selection. Selection of controls with listed 
numbers only was avoided by randomly generating unlisted numbers. There were no 
differences between the cases and controls with regard to gender or age (considering all 
types of cancer), or between the controls and overall population with regard to birth order. 
The quota recruitment process was thus successful. The refusals to take part could have 
been related to the parental socioeconomic status or educational level which appeared 
higher among controls than among Hodgkin’s lymphoma and, to a lesser extent, leukemia 
cases. The control mothers educational levels were very similar to those of the French 
population, but the control fathers’ educational levels were higher 22-24. However, parental 
socioeconomic status and educational level were not associated with a family history of 
cancer in the control group and the results were unchanged after adjustment for these 
variables. We collected no direct information on ethnicity, which might be related to the risk 
of childhood cancer and to history of cancer in relatives. However, excluding the children 
whose any grand-parent was born in Africa or Asia had no influence on the results. 
 
Non-differential misclassification bias was probable since the cancer history data only 
consisted in the mothers’ reports. However, bias was limited by the use of specific closed 
questions and by the fact that the mothers were asked about her and the father's close 
family, i.e. children, siblings and parents. Adults with cancer have been shown to report their 
family history of cancer in first degree relatives quite accurately 25-33. Bondy et al. studied the 
accuracy of data on family history of cancer obtained by interviewing the mothers of children 
and adolescents with sarcoma 34 and reported positive predictive values (PPV) of 88 and 
71% for first- and second-degree relatives of children, respectively. For Perillat et al 17, the 
PPV of mothers’ reports on first-degree relatives of children with leukemia was 100%. The 
sensitivity and specificity of those two studies could not be determined since the negative 
reports were not analyzed.  
Differential recall between cases and controls cannot be excluded. Studies on adults have 
reported no or few differential errors between cancer cases and their controls with respect to 
cancer in relatives 27-31. To our knowledge, no study of accuracy with respect to children has 
been conducted.  
Misclassification may be more marked for paternal than maternal family history of cancer, 
given that mothers were interviewed. However, the ORs associated with the paternal and 
maternal histories were very similar for HL and NHL. This may suggest that the recall bias 
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was weak for lymphomas. Differences were observed for leukemia only, but there would 
appear to be no obvious reason for a recall bias for leukemia and not for lymphoma. 
 
Five previous case-control studies have estimated the association between childhood 
leukemia and family history of cancer 14-18. One study only addressed acute lymphoblastic 
leukemia 18 and a second targeted children aged less than 19 months 14. A positive 
association was found in all the studies. Three reported significant cancer ORs of 1.5 
(95%CI: [1.0-2.1]) 15, 1.5 (95%CI: [1.0-2.2]) 17 and 1.6 (95%CI: [1.2-2.1]) 16; two reported 
significant ORs for a family history of hematopoietic malignancy of 2.7 (95%CI: [1.1-6.9]) 17 
and 2.1 (95%CI: [1.2-3.6]) 18. Six population-based studies on childhood leukaemia linked 
Cancer Registry data with a family database 8-13. One of these studies only addressed 
childhood acute lymphoblastic leukemia 9 and another, acute myeloblastic leukemia 13. With 
the exception of the study by Hasle & Olsen 13, all the registry studies considered first-degree 
relatives only. None of these studies detected a positive association between childhood 
leukemia and family history of cancer, with observed standardized incidence rate ratio from 
0.8 to 1.0. Three of the registry studies 8, 12, 13 did not consider cancer that occurred in 
relatives before the index child’s birth in order to avoid survival bias. Consequently they may 
have failed to detect early-onset malignancies and may have underestimated associations, if 
an earlier onset age was particularly associated with familial cancers. 
Fewer studies have addressed the association between family history of cancer and 
childhood lymphoma 8, 10-12, 15, 35. One of the previous case-control studies reported quite 
similar ORs for childhood leukemia, Hodgkin’s lymphoma and non-Hodgkin's lymphoma (LA: 
OR = 1.5 [1.0-2.1]; LH: OR = 1.4 [0.7-2.9]; LNH: OR = 1.8 [1.0-3.3]) 15. Four of the previous 
registry studies 8, 10-12 also addressed childhood lymphoma, without distinguishing between 
Hodgkin’s and non-Hodgkin's lymphoma. The association with family history of cancer was 
always stronger for lymphoma than for leukemia, with observed standardized incidence rate 
ratio ranging from 1.0 to 1.8. Le Bihan et al. 35 did not observe an increased frequency of 
cancer in the relatives of children with non-Hodgkin's lymphoma in a familial study. 
With regard to associations with specific types of malignancy in relatives, the literature is 
relatively heterogeneous and chance may explain some of the associations. Significant 
positive associations between childhood acute leukemia and a family history of cancer in the 
following disease sites was observed: oral cavity 16; esophagus or stomach 17, colon 16, 17, 
uterus or ovary 16; breast 18; brain 16; melanoma 17; testis 9; and kidney 12. Childhood 
lymphoma, taken as a whole, was shown to be significantly associated with a family history 
of any lymphoma 10, 11 and brain tumor 12.  
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In conclusion, our results support the hypothesis of a familial susceptibility to childhood 
lymphoma but not to childhood leukemia. Besides genetic factors, they may also reflect the 
existence of environmental or infectious risk factors shared by the family members. 
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Table 1: Distribution of cases and controls by the stratification variable, age x gender (16 categories) used for 
quota sampling. 
  Controls  Acute leukemia  Hodgkin's 
lymphoma 
 Non-Hodgkin's 
lymphoma     ALL AML All   
Age (year)  n=1681  n=654 n=101 n=773  n=130  n=163 
 Boys               
 0-1  201 12%  35 17 54 7%  -   1 1% 
 2  79 5%  50 5 55 7%  -   2 1% 
 3  87 5%  57 2 60 8%  1 1%  9 6% 
 4  89 5%  42 4 48 6%  -   11 7% 
 5-6  126 7%  51 6 61 8%  7 5%  24 15% 
 7-8  96 6%  31 5 37 5%  11 8%  18 11% 
 9-11  137 8%  49 9 59 8%  22 17%  23 14% 
 12-14  117 7%  35 6 45 6%  21 16%  26 16% 
 Girls               
 0-1  168 10%  44 19 63 8%  -   -  
 2  74 4%  45 3 48 6%  -   2 1% 
 3  79 5%  47 2 50 6%  -   5 3% 
 4  56 3%  35 3 38 5%  1 1%  5 3% 
 5-6  102 6%  57 5 62 8%  1 1%  7 4% 
 7-8  67 4%  33 5 39 5%  2 2%  9 6% 
 9-11  88 5%  27 7 35 5%  10 8%  8 5% 
 12-14  115 7%  16 3 19 2%  54 42%  13 8% 
ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia 
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Table 2: Socioeconomic and familial characteristics of cases and controls. Odds ratios (OR) and 95% confidence 
intervals (95%CI) were estimated by unconditional regression, adjusted for stratification variable, age x gender. 
Analyses were restricted to children aged more than 4 years for HL and more than 1 year for NHL.  
 Acute leukemia  Hodgkin's lymphoma  Non-hodgkin's lymphoma 
Cases Controls OR 95%CI  Cases Controls OR 95%CI Cases Controls OR 95%CI 
n=773 n=1681   n=128 n=848    n=162 n=1312  
Maternal educational level                   
 ≤ high-school 470 979 1.0  -  91 532 1.0  -  95 795 1.0  - 
 > high-school 303 701 0.9 [0.8 - 1.1]  33 315 0.7 [0.4 - 1.0]  66 516 1.2 [0.8 - 1.6] 
 Missing data  -  1    4 1    1 1   
Paternal educational level **  
   **       
 ≤ high-school 531 1063 1.0  -  102 569 1.0  -  110 851 1.0  - 
 > high-school 234 601 0.8 [0.6 – 0.9]  22 270 0.5 [0.3 - 0.8]  50 445 1.0 [0.7 - 1.4] 
 Missing data 8 17    4 9    2 16   
Professional category
a
 *  
   *       
 Intellectual and 
 scientific jobs, 
 managers and inter-
 mediate professions 282 713 1.0  - 
 
38 360 1.0  - 
 
66 556 1.0 - 
 Administrative and  
 sales workers 226 477 1.2 [1.0 - 1.5] 
 
33 221 1.5 [0.9 - 2.5] 
 
41 356 1,0  [0.7 - 1.5] 
 Service workers 97 215 1.2 [0.9 - 1.5]  29 133 1.9 [1.1 - 3.3]  30 179 1.2 [0.7 - 2.1] 
 Factory and 
 agricultural workers, 
 unemployed  168 274 1.5 [1.2 - 1.9] 
 
28 134 2.1 [1.2 - 3.7] 
 
25 220 1,0 [0.6 - 1.7] 
 Missing data  - 2     -  -     - 1   
Maternal age at interview (year)           
 <35 338 654 1,0  -   16 136 1.0  -   34 393 1.0  -  
 [35-40[ 245 562 0.8 [0.7 - 1.0]  42 337 0.6 [0.3 - 1.2]  59 480 1.1 [0.7 - 1.8] 
 [40-45[ 140 335 0.9 [0.7 - 1.2]  36 260 0.5 [0.2 - 1.0]  45 311 1.2 [0.7 - 2.1] 
 ≥ 45 50 128 0.9 [0.6 - 1.4]  34 114 0.9 [0.4 - 1.8]  24 126 1.5 [0.8 - 2.9] 
 Missing data  2     1     2   
 mean (sd) 36 (6)  36 (6)    41 (6) 39 (5)   39 (6)  37 (5)   
Grand-parents' mean age (year)           
 <60 257 550 1.0  -   11 153 1.0  -   34 331 1,0  -  
 [60-65[ 216 406 1.1 [0,9 - 1,4]  33 199 2.0 [0,9 - 4.1]  32 324 0.8 [0,5 - 1,4] 
 [65-70[ 164 373 0.9 [0,7 - 1,2]  40 243 1.8 [0,9 - 3.7]  47 329 1.1 [0,7 - 1.8] 
 [70-75[ 98 238 0.9 [0,6 - 1,2]  22 162 1.2 [0,6 - 2.7]  37 219 1.3 [0.8 - 2.3] 
 ≥ 75 36 96 0.9 [0,6 - 1,5]  22 78 1.9 [0.8 - 4.3]  11 92 0.9 [0,4 - 1.9] 
 Missing data 2 18     -  13    1 17   
 mean (sd) 63 (7)  63 (7)    68 (7)  66 (7)   66 (7) 65 (7)   
Number of family members            
 6 to 9 182 366 1,0  -   15 140 1.0  -   25 255 1.0  -  
 10 to 12 313 699 0.9 [0.7 - 1.1]  43 347 1.1 [0.6 - 2.1]  73 547 1.3 [0.8 - 2.0] 
 13 to 15 130 337 0.8 [0.6 - 1.1]  35 200 1.4 [0.7 - 2.8]  33 282 1.0 [0.6 - 1.8] 
 16 and more 148 279 1.1 [0.8 - 1.4]  35 161 1.9 [1.0 - 3.7]  31 228 1.2 [0.7 - 2.1] 
 mean (sd) 12 (4)  12 (4)     14 (4) 13 (4)    13 (3) 12 (4)    
a
 Professional category = best occupational activity of child’s mother or father. 
* : 10
-2
 ≤ p <0.05;   **: 10
-3  
≤ p <10
-2
;   ***: p <10
-3
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Table 3: Family history of cancer and childhood hematopoietic malignancies. Odds ratios (OR) and 95% confidence intervals (95%CI) were estimated by unconditional 
regression, adjusted for stratification variable, age x gender. Analyses were restricted to children aged more than 4 years for HL and more than1 year for NHL.  
 Acute leukemia  
Hodgkin's lymphoma 
 
Non-Hodgkin's lymphoma 
ALL   AML   All    
 Cases OR 95%CI  Cases OR 95%CI  Cases OR 95%CI Controls  Cases Controls OR 95%CI  Cases Controls OR 95%CI 
n=654     n=101     n=773    n=1681  n=128 n=848       n=162 n=1312     
Family history of cancer                       
 First-degree relatives                       
 No 640 1.0  -   100 0.9  -   758 1.0  -  1640  120 819 1.0  -   155 1275 1.0  -  
 Yes 14 0.9 [0.5 - 1.6]  1 0.4 [0.1 - 3.0]  15 0.8 [0.4 - 1.4] 41  8 29 2.2 [0.9 - 5.1]  7 37 1.4 [0.6 - 3.1] 
 Second-degree relatives                       
 No 381 1.0 -  62 1.0  -   451 1.0  -  993  53 457 1.0  -   66 748 1.0  -  
 Yes 273 1.1 [0.9 - 1.3]  39 0.8 [0.6 - 1.4]  322 1.1 [0.9 - 1.3] 688  75 391 1.4 [1.0 - 2.1]  96 564 1.8 [1.3 - 2.5] ** 
 First- and second-degree relatives                     
 No 374 1.0 -  62 1.0  -   444 1.0  -  968  50 438 1.0  -   62 726 1.0  -  
 Yes 280 1.1 [0.9 - 1.3]  39 0.9 [0.6 - 1.3]  329 1.0 [0.9 - 1.2] 713  78 410 1.5 [1.0 - 2.2]  100 586 1.8 [1.3 - 2.5] *** 
                       
Number of relatives with cancer                     
 0 374 1.0 -  62 1.0  -   444 1.0  -  968  50 438 1.0  -   62 726 1.0  -  
 1 192 0.9 [0.7 - 1.1]  27 0.8 [0.5 - 1.3]  226 0.9 [0.8 - 1.1] 548  47 310 1.2 [0.8 - 1.8]  71 451 1.7 [1.2 - 2.4] ** 
 2 and more 88 1.5 [1.1 - 2.0] ** 12 1.1 [0.6 - 2.2]  103 1.4 [1.1 - 1.9] ** 165  31 100 2.5 [1.4 - 4.2] *** 29 135 2.2 [1.4 - 3.6] ** 
                       
Earliest cancer onset age in family                     
 No cancer in family 374 1.0 -  62 1.0  -   444 1.0  -  968  50 438 1.0  -   62 726 1.0  -  
 > 60 years 69 0.9 [0.7 - 1.2]  9 0.6 [0.2 - 1.2]  81 0.9 [0.7 - 1.2] 200  18 121 1.0 [0.6 - 1.9]  28 171 1.7 [1.1 - 2.8] * 
 ]45 - 60 years]  91 0.9 [0.7 - 1.2]  21 1.3 [0.8 - 2.2]  116 1.0 [0.8 - 1.3] 259  23 148 1.2 [0.7 - 2.1]  34 211 1.7 [1.1 - 2.6] * 
 ≤ 45 years 94 1.3 [1.0 - 1.7]  7 0.7 [0.4 - 1.5]  104 1.2 [0.9 - 1.6] 196  27 111 2.0 [1.2 - 3.5] * 32 156 2.2 [1.4 - 3.4] ** 
 Missing data 26  - -  2  -  -  28  -  - 58  10 30  -  -  6 43  -  - 
                       
Side of family with cancer                     
 No cancer in family 374 1.0  -   62 1.0  -   444 1.0  -  968  50 438 1.0  -   62 726 1.0  -  
 Only paternal relatives 131 1.2 [0.9 - 1.5]  12 0.7 [0.4 - 1.3]  150 1.2 [0.9 - 1.5] 290  29 166 1.3 [0.8 - 2.2]  38 238 1.7 [1.1 - 2.6] * 
 Only maternal relatives 87 0.7 [0.6 - 1.0] * 20 1.1 [0.6 - 1.8]  108 0.8 [0.6 - 1.0] 305  27 171 1.2 [0.7 - 2.0]  43 251 1.8 [1.2 - 2.8] ** 
 Both sides 62 1.4 [1.0 - 2.0] * 7 0.9 [0.4 - 2.1]  71 1.4 [1.0 - 1.9] 118  22 73 2.5 [1.4 - 4.5] ** 19 97 2.0 [1.1 - 3.5] * 
ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia 
* : 10
-2
 ≤ p <0.05;   **: 10
-3  
≤ p <10
-2
;   ***: p <10
-3
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Table 4: Family history of specific types of cancer (first- and second-degree relatives) and childhood hematopoietic malignancies. Odds ratios (OR) and 95% confidence 
intervals (95%CI) were estimated by unconditional regression, adjusted for stratification variable, age x gender. Analyses were restricted to children aged more than 4 years for 
HL and more than 1 year for NHL. 
 Acute leukemia  
Hodgkin's lymphoma 
 
Non-Hodgkin's lymphoma 
ALL  AML  All    
Cancer in relatives 
Cases OR 95%CI  Cases OR 95%CI  Cases OR 95%CI Controls  Cases Controls OR 95%CI  Cases Controls OR 95%CI 
n=654  n=101     n=773    n=1681  n=128 n=848      n=162 n=1312   
Hematopoietic malignancies 29 1.0 [0.6 - 1.5]  6 1.1 [0.5 - 2.6]  37 1.0 [0.7 - 1.5] 85  15 48 2.0 [1.0 - 3.8] *  9 62 1.0 [0.5 - 2.1] 
Leukemia 16 0.8 [0.5 - 1.5]  3 0.9 [0.3 - 3.0]  20 0.9 [0.5 - 1.5] 52  8 32 1.6 [0.7 - 3.7]  6 39 1.0 [0.4 - 2.5] 
Lymphoma 10 1.1 [0.5 - 2.2]  2 1.1 [0.2 - 4.6]  13 1.1 [0.6 - 2.5] 28  8 15 3.2 [1.2 - 8.0] *  3 20 1.0 [0.3 - 3.6] 
 Hodgkin's 4 1.0 [0.3 - 3.0]  1 1.2 [0.1 – 9.3]  5 1.0 [0.3 - 3.0] 12  4 5 5.4 [1.3 - 22]  *  3 9 2.6 [0.7 - 10] 
 Non-Hodgkin's 7 1.1 [0.5 - 2.8]  1 0.9 [0.1 - 6.6]  9 1.2 [0.5 - 3.0] 18  4 11 2.0 [0.6 - 6.7]  - 13 - - 
Myeloma 4 2.1 [0.6 - 7.9]  1 2.3 [0.3 - 20]  5 2.1 [0.6 - 5.0] 6  - 2 - -  - 4 - - 
Solid cancers 257 1.0 [0.8 - 1.2]  35 0.9 [0.6 - 1.3]  301 1.0 [0.8 - 1.3] 662  74 383 1.5 [1.0 - 2.2] *  94 550 1.8 [1.3 - 2.6] *** 
Oral cavity, ENT 36 1.4 [0.9 - 2.2]  5 1.2 [0.5 - 3.2]  42 1.4 [1.0 - 2.0] 67  8 34 1.6 [0.7 - 3.7]  11 52 1.8 [0.9 - 3.6] 
Lung 38 0.7 [0.5 - 1.1]  6 0.8 [0.3 - 1.9]  46 0.7 [0.5 - 1.1] 135  18 84 1.3 [0.7 - 2.3]  20 118 1.3 [0.8 - 2.2] 
Digestive 73 1.2 [0.9 - 1.6]  9 1.0 [0.5 - 1.9]  83 1.1 [0.8 - 1.6] 163  20 96 1.5 [0.9 - 2.6]  28 139 1.7 [1.1 - 2.7] * 
 Esophagus, stomach 20 1.2 [0.7 - 2.0]  - - -  20 1.0 [0.6 - 1.9] 43  5 24 1.4 [0.5 - 3.9]  5 39 1.0 [0.4 - 2.7] 
 Liver 22 1.4 [0.8 - 2.3]  3 1.3 [0.4 - 4.2]  26 1.4 [0.8 - 2.3] 43  4 29 0.8 [0.3 - 2.5]  8 38 1.6 [0.7 - 3.5] 
 Colon, rectum, anus 23 1.1 [0.7 - 1.8]  3 0.9 [0.3 - 2.8]  26 1.0 [0.6 - 1.7] 56  9 30 2.4 [1.0 - 5.4] *  12 44 2.4 [1.2 - 4.7] * 
 Pancreas 8 1.4 [0.6 - 3.4]  2 2.6 [0.6 - 12]  11 1.7 [0.7 - 4.0] 14  4 7 3.2 [0.8 - 13]  4 12 3.4 [1.0 - 11]  * 
 Other or NOS 9 1.6 [0.7 - 3.7]  1 1.2 [0.2 - 9.7]  10 1.5 [0.7 - 3.5] 15  2 10 1.6 [0.3 - 8.0]  - 13 - - 
Breast 63 1.1 [0.8 - 1.5]  7 0.7 [0.3 - 1.6]  73 1.0 [0.8 - 1.5] 157  17 92 1.1 [0.6 - 2.0]  21 124 1.3 [0.8 - 2.2] 
Thyroid 8 2.4 [0.9 - 6.3]  1 1.7 [0.2 - 14]  9 2.3 [0.9 - 6.4] 9  2 6 3.0 [0.6 - 15]  1 7 1.0 [0.1 - 8.1] 
Skin 10 0.9 [0.4 - 1.9]  1 0.7 [0.1 - 5.2]  11 0.9 [0.4 - 1.9] 26  2 17 0.8 [0.2 - 3.5]  3 24 0.9 [0.3 - 3.0] 
 Melanoma 2 0.7 [0.1 - 3.5]  1 2.0 [0.2 - 17]  3 0.9 [0.2 - 3.5] 8  1 5 1.2 [0.1 - 11]  2 7 2.0 [0.3 - 10] 
 Other or NOS 8 0.9 [0.4 - 2.2]  1 1.0 [0.1 - 7.3]  9 0.9 [0.4 - 2.1] 19  1 13 0.6 [0.1 - 4.6]  1 18 0.4 [0.1 - 2.9] 
Bone 5 0.6 [0.2 - 1.5]  - - -  5 0.5 [0.2 - 1.3] 20  3 11 2.0 [0.5 - 8.3]  - 17 - - 
Genitourinary 74 1.2 [0.9 - 1.6]  13 1.4 [0.7 - 2.5]  91 1.2 [0.9 - 1.6] 164  21 97 1.4 [0.8 - 2.4]  31 133 1.9 [1.2 - 3.0] ** 
 Kidney 5 0.9 [0.3 - 2.4]  - - -  6 0.9 [0.3 - 2.1] 16  5 10 3.2 [1.0 - 10]  2 14 1.1 [0.2 - 4.8] 
 Bladder 10 1.3 [0.6 - 2.7]  1 0.8 [0.1 - 5.8]  11 1.2 [0.6 - 2.5] 20  1 15 0.5 [0.1 - 4.1]  - 18 - - 
 Uterus, ovary 33 1.5 [0.9 - 2.3]  7 2.1 [0.9 - 4.8]  42 1.6 [1.1 - 2.4] * 57  6 34 1.1 [0.4 - 2.8]  16 48 2.6 [1.4 - 4.8] ** 
 Prostate 28 1.0 [0.7 - 1.7]  6 1.5 [0.6 - 3.5]  35 1.1 [0.7 - 1.7] 71  9 38 1.3 [0.6 - 2.8]  11 54 1.6 [0.8 - 3.1] 
 Testis 2 0.8 [0.2 - 4.3]  1 3.0 [0.4 - 26]  3 1.0 [0.3 - 4.1] 6  - 3 - -  3 5 6.3 [1.4 - 29]  * 
Brain 17 1.4 [0.8 - 2.6]  2 1.1 [0.3 - 4.8]  19 1.3 [0.7 - 2.4] 32  4 19 1.2 [0.4 - 3.7]  6 27 1.6 [0.6 - 4.0] 
Other or NOS 22 0.9 [0.5 - 1.5]  1 0.2 [0.0 - 1.8]  23 0.8 [0.5 - 1.5] 65  10 35 2.2 [1.0 - 4.8] * 9 52 1.3 [0.6 - 2.7] 
ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; ENT = Ear Nose Throat; NOS = site not otherwise specified  
* : 10
-2
 ≤ p <0.05;   **: 10
-3  
≤ p <10
-2
;   ***: p <10
-3 
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